Show simple item record

dc.contributor.authorFusi, A.
dc.contributor.authorGupta, A.
dc.contributor.authorLorigan, Paul C
dc.contributor.authorSmith, P. L.
dc.contributor.authorBowles, M.
dc.date.accessioned2022-11-30T10:21:30Z
dc.date.available2022-11-30T10:21:30Z
dc.date.issued2022en
dc.identifier.citationFusi A, Gupta A, Lorigan P, Smith PL, Bowles M. A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM101-015 trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302373.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.9554en
dc.identifier.urihttp://hdl.handle.net/10541/625823
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9554en
dc.titleA phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM101-015 trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentSt. George's University Hospitals NHS Foundation Trust, St. George's University of London, Londonen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record